Astria Therapeutics, Inc. (ATXS) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ATXS Revenue Growth
ATXS Revenue Analysis (2013–2024)
As of May 8, 2026, Astria Therapeutics, Inc. (ATXS) generated trailing twelve-month (TTM) revenue of $706,000. The most recent quarter (Q3 2025) recorded $706,000 in revenue.
Looking at the longer-term picture, ATXS's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $500,000 in 2017.
When compared to Healthcare sector peers including BCAB (-81.8% YoY), HALO (+37.6% YoY), and ARDX (+18.2% YoY). Compare ATXS vs BCAB →
ATXS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ATXSCurrent | $706,000 | - | - | - | |
 BCAB | $2M | -81.8% | +36.1% | -2965.3% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% |
ATXS Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-111,558,000 | - |
| 2023 | $0 | - | $0 | - | $-83,030,000 | - |
| 2022 | $0 | - | $0 | - | $-53,503,000 | - |
| 2021 | $0 | - | $0 | - | $-194,976,000 | - |
| 2020 | $0 | - | $0 | - | $-37,435,000 | - |
| 2019 | $0 | - | $0 | - | $-27,088,000 | - |
| 2018 | $0 | -100.0% | $-119,000 | - | $-26,371,000 | - |
| 2017 | $500K | - | $500K | 100.0% | $-27,094,000 | -5418.8% |
| 2016 | $0 | - | $-395,000 | - | $-35,558,000 | - |
| 2015 | $0 | - | $-202,000 | - | $-31,659,000 | - |
See ATXS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ATXS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ATXS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonATXS — Frequently Asked Questions
Quick answers to the most common questions about buying ATXS stock.
Is ATXS's revenue growth accelerating or slowing?
ATXS TTM revenue: $706000.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ATXS's long-term revenue growth rate?
Astria Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is ATXS's revenue distributed by segment?
ATXS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.